United States
The company's focus on metastatic cancer research is timely as current drug discovery efforts have not resulted in significant improvements in patient survival, drug delivery specificity, or the mitigation of adverse side effects. MetasTx has made significant strides in their studies, highlighting the pivotal role of PAK1 in regulating the epithelial-to-mesenchymal transition (EMT), a crucial process in the transformation of early cancer cells into metastatic ones. Their product MTX-101 exhibits remarkable stability and efficacy in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer, with potential applications across solid tumor cancers.
Founded in 2021 and headquartered in the United States, MetasTx recently secured a $100.00K Pre Seed Round investment on 06 December 2023, with backing from Innovation Works and AlphaLab Health. The promising nature of their research and development makes MetasTx a compelling venture for potential investors seeking to make a meaningful impact in the fight against cancer metastasis.
